department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

BRISTOL MYERS SQUIBB CO ($BMY) · catalysts · pharmadog

← back to BRISTOL MYERS SQUIBB CO

Catalysts for $BMY

99 tracked

BRISTOL MYERS SQUIBB CO earnings

BRISTOL MYERS SQUIBB CO

BRISTOL MYERS SQUIBB CO earnings

BRISTOL MYERS SQUIBB CO

Azacitidine Injection shortage — Bristol Myers Squibb Co.

BRISTOL MYERS SQUIBB CO

OPDIVO (NIVOLUMAB) — FDA approval

INREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approval

OPDIVO QVANTIG (NIVOLUMAB) — FDA approval

(hyaluronidase (recombinant, human) + nivolumab)

Bristol-Myers Squibb Company recall (Cls II)

BRISTOL MYERS SQUIBB CO

OPDIVO QVANTIG (NIVOLUMAB) — FDA approval

(hyaluronidase (recombinant, human) + nivolumab)

OPDIVO QVANTIG (NIVOLUMAB) — FDA approval

(hyaluronidase (recombinant, human) + nivolumab)

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO QVANTIG (NIVOLUMAB) — FDA approval

(hyaluronidase (recombinant, human) + nivolumab)

OPDIVO (NIVOLUMAB) — FDA approval

INREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO QVANTIG (NIVOLUMAB) — FDA approval

(hyaluronidase (recombinant, human) + nivolumab)

OPDIVO (NIVOLUMAB) — FDA approval

INREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

INREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

OPDIVO (NIVOLUMAB) — FDA approval

← prevpage 1 of 4next →

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%

$BMY56.70-2.46%